Subhash Sinha

Subhash Sinha serves as Professor of Research in Neuroscience at the Brain and Mind Research Institute, Weill Cornell Medical College, Cornell University. His work bridges molecular neuroscience and therapeutic development for neurodegenerative disorders, with emphasis on Alzheimer's disease mechanisms and intervention strategies.

His academic foundation includes:

• B.Sc. from Patna University (India), 1980
• M.Sc. from Patna University (India), 1983
• Ph.D. from Banaras Hindu University (India), 1988

Dr. Sinha's research integrates molecular biology, immunology, and computational approaches to investigate cGAS-STING pathway dysregulation in neurodegeneration. Key interests include tau pathology mechanisms, microglial senescence, sex-specific demyelination processes, and development of cGAS inhibitors and tau-targeted immunotherapies. His work explores genetic resilience factors like APOE3-R136S and cellular mechanisms underlying cognitive preservation.

Analysis of his 15 most recent publications reveals a dominant focus on cGAS inhibition (appearing in 7 articles), tau pathology (10 articles), and neuroinflammation (12 articles). Methodologically, his team employs iPSC models, murine disease systems, high-throughput screening, and molecular modeling to identify therapeutic targets with translational potential for Alzheimer's disease.

Dr. Sinha currently leads or co-leads seven major research initiatives including NIH-funded projects on cGAS inhibitors (NIA, 2021-2026) and acetylated tau immunotherapy (NIA, 2025-2026). His grant portfolio spans the Cure Alzheimer’s Fund, Rainwater Charitable Foundation, and Harrington Discovery Institute, focusing on target validation, lead optimization, and disease mechanism studies.

He maintains active industry collaborations as Consultant for Aeton Therapeutics Inc. and CGA Therapeuticals Incorporated, and holds Leadership Roles at LSG Therapeutics, LLC, facilitating translation of academic discoveries into therapeutic pipelines.